New York, July 24, 2026, 06:06 EDT
- The stock finished at $32.74, gaining 3.4%, as the S&P 500 declined 1.2%.
- Leerink estimates peptide sales at $440 million, representing roughly 15% of Hims’ projected 2026 revenue midpoint.
Hims & Hers Health NYSE:HIMS finished up 3.4% at $32.74 on Thursday. Four unapproved peptides received backing from U.S. advisers for pharmacy compounding, opening the door to a potential $440 million sales opportunity in 2027.
The projection represents about 15% of Hims’ $2.9 billion midpoint for revenue guidance. This figure comes from analyst forecasts, not from company guidance.
The schedule is significant. The vote does not carry legal force, and the official rulemaking process may last as long as one year.
As of 06:06 EDT, NYSE core trading remained closed. Pre-market trading occurred prior to the 9:30 a.m. session.
Hims dropped 4.5% over the past full week, closing at $32.84 on July 17. The stock edged down a further 0.3% by Thursday.
On Thursday, Hims surpassed the S&P 500 by 4.6 percentage points, while the index declined 1.2%.
The potential increase in revenue is significant. The range is still wide.
| Case | Peptide market | Hims share | Estimated Hims sales | Share of 2026 revenue midpoint |
|---|---|---|---|---|
| Leerink projection | $2.2 billion | 20% | $440 million | 15% |
| Illustrative upper scenario | $3.3 billion | 20% | $660 million | 23% |
This is an initial, sample calculation. Needham’s cited report does not include a Hims share projection. Neither row reflects official company forecasts.
The high scenario uses Leerink’s share projection alongside Needham’s higher market estimate. It indicates the potential gains should demand hit the top forecast.
Michael Cherny, an analyst at Leerink, maintained a Market Perform rating with a price target of $25, Barron’s reported. The target is 24% less than the stock’s closing price on Thursday.
Hims acquired a manufacturing plant with peptide capabilities in 2025. CEO Andrew Dudum stated in May the firm could move into the category “at scale.” Reuters
Hims’ Chief Medical Officer Anant Vinjamoori told the panel on Thursday the company stands to gain commercially. A launch date has not been determined.
Sales at present are driven largely by GLP-1 medications and existing wellness offerings. Peptides are expected to complement, not substitute, the current main products.
Panelist Elizabeth Rebello said, “I’m concerned that we’re responding to a market-induced demand rather than a decision based in solid science.” Reuters
The FDA will discuss emideltide, Semax and Epitalon in Friday’s session. The meeting is scheduled to conclude at 4:15 p.m. EDT.
Options markets are pricing in a 14% swing in either direction by the end of the month, Reuters said. Hims is scheduled to announce its second-quarter earnings on August 10.
Risks are still significant. The FDA is not required to follow the panel’s recommendation. There is limited safety data available, and compounded products lack FDA approval.
Related articles: NYSE:HIMS
